New combo pill plus insulin shows promise for type 2 diabetes

NCT ID NCT02081599

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding the diabetes pill teneligliptin to insulin helps people with type 2 diabetes control their blood sugar better. 148 Japanese adults who were already on a stable insulin dose took either teneligliptin or a placebo for 16 weeks, with an extension up to 52 weeks. The main goal was to see if HbA1c (a measure of average blood sugar) improved more with the combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teneligliptin (a diabetes pill that helps lower blood sugar)
What this could lead to: If it works, this could offer a new combination option for people with type 2 diabetes who need better blood sugar control despite using insulin.
What could go wrong: This is a completed Phase 4 study in a specific population (Japanese patients), so results may not apply to other groups. Adding another drug also raises the chance of side effects like low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Investigational site

Chuo-ku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.